Related Experiment Videos
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung
1Division of Hematology/Oncology, Sungkyunkwan University, College of Medicine, Samsung Medical Center, Seoul, Korea.
Background:
TGF-beta type II receptor is considered as one of the tumor suppressor genes, and altered expression of TGF-beta RII has been found in many kinds of cancers.
Materials And Methods:
Seven NSCLC cell lines and 21 surgically resected NSCLC tissues were obtained. The growth inhibition by TGF-beta 1 was examined by MTT assay. Northern blot and Southern blot analysis were performed for TGF-beta 1 and TGF-beta RII in NSCLC cell lines. TGF-beta 1 and TGF-beta RII expression were analyzed by immunohistochemistry (IHC) in 21 surgically resected NSCLC tissues.
Results:
Six of 7 NSCLC cell lines were resistant to TGF-beta 1. Southern blot analysis for TGF-beta 1 and TGF-beta RII showed no genetic changes. However, mRNAs of TGF-beta RII were barely detectable in 3 of 7 cell lines, and mRNAs of TGF-beta 1 were almost undetectable in 2 of 7. IHC revealed decreased TGF-beta RII expression in 6 of 21 surgically resected NSCLC tissues (5 adenocarcinomas, 1 sarcomatoid carcinoma). Being analyzed by the histologic subtypes, TGF-beta RII decreased in 5 of 8 adenocarcinomas but in only 1 of 13 non-adenocarcinomas (p = 0.0139). On the other hand, TGF-beta 1 was expressed at a higher level in 20 of 21 tumors.
Conclusion:
These results suggest that decreased TGF-beta RII expression may play a role in human lung carcinogenesis, especially in adenocarcinoma.
Insights
Decreased expression of TGF-beta type II receptor (TGF-beta RII) is linked to lung cancer development, particularly in adenocarcinoma. This suggests TGF-beta RII may act as a tumor suppressor in lung carcinogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Transforming growth factor-beta type II receptor (TGF-beta RII) is recognized as a tumor suppressor gene.
- Altered TGF-beta RII expression is observed in various cancers.
Purpose of the Study:
- To investigate the role of TGF-beta RII expression in non-small cell lung cancer (NSCLC).
- To analyze the correlation between TGF-beta RII expression and NSCLC subtypes.
Main Methods:
- Analysis of TGF-beta 1 and TGF-beta RII expression in 7 NSCLC cell lines and 21 tumor tissues.
- Utilized MTT assay, Northern blot, Southern blot, and immunohistochemistry (IHC).
Main Results:
- Six of 7 NSCLC cell lines exhibited resistance to TGF-beta 1.
- No genetic alterations in TGF-beta 1 or TGF-beta RII were detected.
- Decreased TGF-beta RII mRNA was found in 3 cell lines; decreased protein expression in 6 tumor tissues.
- Reduced TGF-beta RII expression was significantly associated with adenocarcinoma (p = 0.0139).
- Elevated TGF-beta 1 expression was observed in 20 of 21 tumors.
Conclusions:
- Reduced TGF-beta RII expression is implicated in human lung carcinogenesis.
- This downregulation is particularly relevant in lung adenocarcinoma.